Share this :
Post on twitter:
Dx2010: Markers to markets
By John McCulloch @ MaRS
July 19, 2010
The future of genetics looks bright
What’s the future of genetic diagnostics? Where do the commercialization opportunities exist? Now we know.
On June 22, the Ontario Genomics Institute and MaRS Future of MedicineTM jointly held “Dx2010: Markers to Markets” – a workshop focused on best practices and regulatory considerations for developing gene-based diagnostic and prognostic tests.
The invitation-only event drew over 70 representatives from developing biotech firms, multinationals, legal firms, investment groups and government.
If you missed this event, we now have content from the workshop available to the public.
Video:
Presentations:
We hope you will enjoy these insights from the leading edge of gene-based diagnostic development!
Stay tuned for more OGI/MaRS Future of MedicineTM joint events on additional commercialization topics going forward.
Related Blogs
The future of medicine's so bright
Imagine a world where…
drugs work reliably
no one ever gets sick from their prescriptions
harmful properties are designed out of all new drugs
critically-ill patients entering the ICU expect a po ArcticDX licenses genes for cancer test
An international team of researchers in colorectal cancer published the results of a study that links specific genes to the risk of colorectal cancer in this week’s Nature Genetics. Together, t Arctic is heating upLife Sciences Ontario (LSO) has appointed long-time MaRS client ArcticDX the 2012 Emerging Life Sciences Company of the Year. ArcticDX is a molecular diagnostic company that is commercializing progno Clients wow at BioPartnering
Our life sciences and health care practice took three MaRS clients on the road to Vancouver last month to attend the 2011 BioPartnering North America (BPNA) meeting, the first major life sciences bus iPS cells take a beating
It sounded too good to be true – the addition of a handful of genes to an adult skin cell would transform it into a stem cell capable of being adapted into any tissue type.
The excitement at Shinya One step closer to better chemo for cancer
Congratulations to MaRS client RNA Diagnostics Inc., winners of the 2010 sanofi pasteur Healthcare and Biotechnology Venture Challenge (HBVC)!
Rna Diagnostics’ product target is called RNA Disr
Tags: diagnostics, Dx2010, genetics, health care, John McCulloch, life sciences, OGI, policy
